2013
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2002
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Rainey PM, Friedland GH, Snidow JW, McCance‐Katz E, Mitchell SM, Andrews L, Lane B, Jatlow P. The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects. American Journal On Addictions 2002, 11: 66-74. PMID: 11876585, DOI: 10.1080/10550490252801657.Peer-Reviewed Original ResearchConceptsSerum concentrationsCombination tabletSerum concentration-time curveMethadone dose changesMethadone serum concentrationsMaximum serum concentrationOpiate-dependent subjectsConcentration-time curveVolume of distributionCombination pharmacotherapyMethadone pharmacokineticsTerminal eliminationCo-administrationDose changesMean areaSignificant differencesPharmacokineticsSubjectsSubject studyHIVPharmacotherapyPatientsAdministration